Pharmacy compounding threshold of 20% being considered as trigger for FDA oversight in Hill discussions.
Executive Summary
PHARMACY COMPOUNDING THRESHOLD OF 20% BEING DISCUSSED as a trigger-point for FDA involvement in oversight of compounded products introduced into interstate commerce. The 20% threshold is one of several being considered by FDA, lawmakers and pharmacy groups in a series of meetings on Capitol Hill preceding further floor discussions of the FDA reform bill (S 830) after August recess ends Sept. 2.